WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: Drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 6, 1999, Pages 498-504

  Souid, Abdul Kader ^a   Fahey, Robert C ^b   Dubowy, Ronald L ^a   Newton, Gerald L ^b   Bernstein, Mark L ^c  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Chemoprotection; Monobromobimane; Pediatric oncology; Thiols; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKYLATING AGENT; AMIFOSTINE; CYCLOPHOSPHAMIDE; CYSTEINE; GLUTATHIONE; IFOSFAMIDE; MESNA; THIOL;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EWING SARCOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BONE NEOPLASMS; CHILD; CYCLOPHOSPHAMIDE; CYSTEINE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; KINETICS; MALE; MESNA; RADIATION-PROTECTIVE AGENTS; SARCOMA, EWING'S; SULFHYDRYL COMPOUNDS; TIME FACTORS;

EID: 0032751755     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051124     Document Type: Article

References (23)

1. 1. Aguilera JA, Newton GL, Fahey RC, Ward JF (1992) Thiol uptake by Chinese V79 cells and aerobic radioprotection as a function of the net charge on the thiol. Radiat Res 130: 194
2. 2. Amifostine (Ethyol®): current and future applications in cytoprotection (1996). Eur J Cancer 32A [Suppl. 4]: S1-S49
3. 3. Applications of amifostine in cancer treatment (1996). Semin Oncol 23 [Suppl. 8]: 1-99
4. 4. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70
5. 5. Fahey RC, Newton GL (1985) Measurement of WR-2721, WR-1065, and WR-33278 in plasma. Int J Radiat Oncol Biol Phys 11: 1193
6. 6. Fahey RC, Newton GL (1987) Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. Methods Enzymol 143: 85
7. 7. Issels RD, Nagele A (1989) Promotion of cysteine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res 49: 2082
8. 8. Jocelyn PC (1987) Spectrophotometric assay of thiols. Methods Enzymol 143: 44
9. 9. Korst AEC, Gall HE, Vermorken JB, van der Vijgh WJF (1996) Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 39: 162
10. 10. Korst AEC, Eeltink CM, Vermorken JB, van der Vijgh WJF (1997) Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33: 1425
11. 11. Kosower NS, Kosower EM (1987) Thiol labeling with bromobimanes. Methods Enzymol 143: 76
12. 12. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T (1994) Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 34: 132
13. 13. Mangold DJ, Huelle BK, Miller MA, Geary RS, Sanchez-Barona DOT, Swynnerton NF, Fleckenstein L, Ludden TM (1990) Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metab Dispos 18: 281
14. 14. Mansoor MA, Svardal AM, Ueland PM (1992) Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 200: 218
15. 15. Newton GL, Fahey RC (1995) Determination of biothiols by bromobimane labeling and high-performance liquid chromatography. Methods Enzymol 251: 148
16. 16. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, Kligerman MM (1986) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501
17. 17. Shaw LM, Bonner HS, Brown DQ (1994) Metabolic pathway of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 22: 895
18. 18. Shaw LM, Bonner HS, Schuchter L, Schiller JH, Nakashi MA, Lieberman R (1996) Population pharmacokinetics of amifostine in cancer patients (abstract 1515). Proc Am Soc Clin Oncol 15: 478
19. 19. Smoluk GD, Fahey RC, Ward JF (1986) Equilibrium dialysis studies of the binding of radioprotector compounds to DNA. Radiat Res 107: 194
20. 20. Smoluk GD, Fahey RC, Ward JF (1988) Interaction of glutathione and other low-molecular-weight thiols with DNA: evidence for counterion condensation and coion depletion near DNA. Radiat Res 114: 3
21. 21. Souid AK, Newton GL, Dubowy RL, Fahey RC, Bernstein ML (1998) Determination of the cytoprotective agent WR-2721 (amifostine, Ethyol®) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol 42: 400
22. 22. Treskes M, van der Vijgh WJF (1993) WR-2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 33: 93 (and references therein)
23. 23. Utley JF, Seaver N, Newton GL, Fahey RC (1984) Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 10: 1525